LabReady

Name

LabReady

Legal name

Vax-Immune, LLC

Website

https://labready.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Point-of-Care Molecular Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industries

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Rapid On-Site Environmental Testing Kits & Instruments (Lateral Flow, PCR, ATP Devices) (AFALAEAK)

Keywords

• Molecular diagnostics
• QPCR testing devices
• Point-of-care diagnostics
• Multiplex pathogen detection
• Portable diagnostic hardware

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Diagnostic Device and Consumables: The company sells portable qPCR diagnostic devices along with single-use cartridge consumables for testing. The 'no upfront costs' messaging suggests a consumables-based or rental model where the device may be provided at low or no initial cost, with revenue generated through ongoing cartridge purchases.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

LabReady develops and offers MyLabReady, a portable, pocket-sized multiplex qPCR diagnostic device that combines a rugged base-unit analyzer with single-use cartridges featuring integrated swabs. The system uses onboard AI to verify diagnostic results and can detect up to five pathogens simultaneously in minutes at the point of need, without requiring a laboratory, refrigeration, or specialized training. Products are currently in development and pending regulatory approval, with access available through an early access program.

Product overview

LabReady offers a single unified product, MyLabReady, which is a portable qPCR diagnostic device designed to bring lab-quality testing to point-of-need settings. The product consists of a rugged, one-button analyzer base unit and disposable cartridges with integrated swabs. It leverages AI to verify diagnostic results and can detect up to five pathogens in minutes, targeting use cases across clinics, farms, and factories.

Differentiator

Problem solved

Functional benefit

Brands

• MyLabReady: Pocket PCR lab device that delivers diagnostic quality multiplex qPCR results in minutes with AI verification, detecting up to five pathogens with no lab, no refrigeration, and no specialized training required.

Products and services

• MyLabReady Portable, pocket-sized multiplex qPCR diagnostic device consisting of a rugged base-unit analyzer and single-use cartridges with integrated swabs. Uses onboard AI to verify results and detects up to five pathogens simultaneously in minutes. Designed for point-of-need use by clinics, farms, and factories without requiring a lab, refrigeration, or specialized training.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Abbott (ID NOW): ID NOW is a rapid molecular POC platform used in clinics and pharmacies. Broader diagnostics incumbent with significant overlap on rapid molecular testing at the point of need.
• Mesa Labs: Supplies detection and monitoring instruments including microbial/environmental testing tools used in regulated industries. Comparable on the industrial/factory pathogen and contamination testing use cases targeting LabReady's factory segment.
• QuidelOrtho: Broad IVD portfolio including rapid immunoassays and molecular diagnostics (e.g., Savanna). Comparable as a diversified diagnostics incumbent active in rapid point-of-care testing.
• Roche Diagnostics (cobas Liat): Markets the cobas Liat rapid PCR platform for CLIA-waived point-of-care testing. Directly comparable single-cartridge qPCR offering with strong global distribution and a broad IVD portfolio beyond POC.

Direct peers

• Cepheid (Danaher): Maker of the GeneXpert system, the dominant FDA-cleared multiplex rapid PCR platform deployed in clinical and non-clinical settings. Most directly comparable to LabReady on multiplex qPCR and point-of-need testing, though at vastly greater scale and with a deep installed base.
• bioMérieux (BioFire): Sells the FilmArray multiplex PCR system for syndromic infectious-disease panels. Direct competitor in the POC multiplex qPCR space with established clinical and hospital market share.

Emerging players

• Binx Health: Developer of rapid molecular testing (io system) for CLIA-waived point-of-care settings. Comparable on cartridge-based rapid qPCR/molecular testing at the point of need.
• Visby Medical: Develops a palm-sized, single-use PCR device for infectious disease testing without separate instrumentation. Closest analog to LabReady's pocket-sized, no-infrastructure value proposition.
• T2 Biosystems: Develops proprietary molecular diagnostic platforms for sepsis and other infections directly from whole blood. Comparable as a specialized molecular diagnostics player competing in rapid, decentralized infectious-disease detection.
• Cue Health: Connected molecular testing platform for at-home and point-of-need use. Comparable on portable, AI/cloud-connected rapid molecular diagnostics for non-laboratory users.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/labreadydx
• Xx.com/lab_ready
• Facebookfacebook.com/LabReadyProducts

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LabReady